Cite
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
MLA
David Fitchett, et al. “Mediators of the Improvement in Heart Failure Outcomes with Empagliflozin in the EMPA‐REG OUTCOME Trial.” ESC Heart Failure, vol. 8, no. 6, Dec. 2021, pp. 4517–27. EBSCOhost, https://doi.org/10.1002/ehf2.13615.
APA
David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, & Faiez Zannad. (2021). Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial. ESC Heart Failure, 8(6), 4517–4527. https://doi.org/10.1002/ehf2.13615
Chicago
David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, et al. 2021. “Mediators of the Improvement in Heart Failure Outcomes with Empagliflozin in the EMPA‐REG OUTCOME Trial.” ESC Heart Failure 8 (6): 4517–27. doi:10.1002/ehf2.13615.